about you us ladies accomplishments will and our and morning. Thank bit over by call gentlemen. morning I you, talking quarter. the for a good joining Thank begin our this Lauren
on our of is a earnings success to our we As will the remain call, call, transformation are investment to Execution in areas Avadel. in We nocturia. of to critical and next XX education laid our last XX period we has our pleased to last several to of with in we that say months. X delivered Phase progress our the NOCTIVA the objectives over the to around as shared results continued come. enrollment and and were both to launch team improve I much which trial more am out continue
FTXXX, oxybate narcolepsy. with start our Let’s once-nightly sodium for
out we approximately FTXXX. patients we the trial Over X randomized executed have for XX%. and months, quarter X August, last the and laid XX% to REST-ON enrolled In enroll continued we over were have we that of Phase the have new objectives our indicated over
we have we patients. about were and programs initiated actively our to recently Sleep to where we sites have screening We patients. are campaign new a the a our enrollment designed in new XX Australia, successfully of the of are new clinical and patient-focused Two are implemented initiated that of sites, all ad in patient number study. our program Meeting, accelerate referral which to patients Importantly, patient opt-in receive education and of hosted program. Annual XXX with Sydney, XXth over expanding is day pool a In XX physicians DownUnder the naïve unavailable of oxybate sodium information oxybate trial we attendees had the sponsor the referral thereby where now
our very in actively two optimistic sites and Australia patients. our reception are We are about screening
shortly initiatives. our have Australia that the will new we both others. come an on-board potentially and we we site of recall, and may additional fruits are in believe U.S., the In you seeing As that
that course does first mean it month will mean and number have is study scheduled the not remainder For example being every up we demonstrate the doesn’t currently into of that or patients that seeing renewed we a visit. prescreened, however new sites, have heading of vigor that of had signs because being be at of all end screened these study. largest are this sites, tactics patients positive older will What we the either This our participants. and new sustained does this for
in process directed several know, team me of you chosen continue patient new we offer to senior our you still time will new screening and and weeks back on, as Members commitment have look forward the have and with work presence for significant long participating through providing have visiting we our this that of our clinical campaigns including to more recently we half and sites commit are of increasing made in to ad not that follow sites we updates. on personally and date have With because are a enroll all site optimistic is the the As in. trial sites launched, to our to focused initiations patients. only patient management enroll last and
in launch NOCTIVA, only not NOCTIVA, Now metrics seen standpoint, also to have the product market looking at building many total when as progress has lower we in a although This we we in than similar generated a undertake prescribers From Nocturia. launch we consistent total for have is as overall since new made made been prescriptions. initially but in both also important growth of NOCTIVA. have prescription new expected, the a and progress the demand of new
unique trends evaluating since As with total and been prescriptions when over now periods. and are X,XXX. launch X,XXX eight week both has to prior week prescribers prescriptions compared are four approaching consistent growth Total
and prescribing of this of of to base, prescriptions current to our XX% our NOCTIVA indemnification This see and believe their is serves Nocturia, began we of been level treated or their acceleration the trial develop with and dispense important continued of coming are research usage. prescriber an in two-thirds at from physician Nocturia, of deeper usage, Looking experience tying of of we after speak dedication to those We important on relevance from those the further in all suffering confirm This has professionals began NOCTIVA the expansion pool. it confirmed launch as patient total a gaining prescribers. of see prescribing. comfort to confidence healthcare since approximately an and importance and patients they highly
In market analog which of indicates NOCTIVA than overactive physicians commercially from first XX of increase an one quarter From covered has in just the bladder most covered data of available to used second targeted use our months. for important in had more approximately months preferred commercial commercially expect approximately access From are our NOCTIVA widely being perspective, with research the ongoing over a next as addition, their X very market studies that ended brands million brand. six XXX third perspective year. an over market coverage its intent-to-treat of XX% lives recent million the we of
PBM. In recently coverage D. Signed D now addition, we first have with improved a and contract Part have approximately we major in Medicare for X million effect, finalized lives Part our in
contracts with as can the Part how the recognized XX launch. months formulary months D and this contract earned pleased have be especially in of difficult we are We wins first XX to
August satisfied to early have target improved due nocturia. While current their demand increased markedly to and to our of our brand level we important not awareness progress XX%, From performance prescriber are other metrics. demand terms in revenue, very in base our and the on perceptions making launch we with from are XX% we unaided on to up conversion of bother
by indicates Our over times report being XX% night. two least per waking bothered of patients’ at that research also
per to significant points initially prescribers X now bothered this at target X report to our that night. occurred occur other our at seriously. prescriber per However, a is take to points in only beginning more or now night. words, or stating targeted more begins believed X base shift They belief nocturia it In
that in this be the We have increased healthcare compares workup is important consideration for also XX% screening targeted important. of less to the XX% patients. nocturia of now an practitioners launch. belief than at believe should This Over
Council, caregiver see In potential launched highlights addition we nocturia. related women’s It on organizations groups coalition and millions of XX need and headway are recently educate NOCTIVA organizations, advocacy and to making educational prominent that who Nocturia representing front, unmet physician patient men us a of these have to healthcare constituents urologic the their to all groups. They stakeholders important patients. have also the joined the
bring of health solutions, to the seek to this light impacts condition wealth NOCTIVA. dramatically collectively and as such potential that will offers and patients We under-treated
work practitioners about healthcare treatment that paradigm recognize the must quality also physicians, with on shifting its symptoms engage life. continue we we we and their of patients their impact of to begin and As to their health help their
that their The to bathroom wake by to recently conducted our about physician opportunity We X,XXX was large While sufferers. further nocturia true American Poll one-third very over further is of researched of simply adults know Nocturia over this of believe education to a normal health is adults. night the and patients’ times for published market underinformed their by and demonstrated it report a over NOCTIVA. have go XX% to and not part U.S. being for silent and disruptive and an and that that of demonstrated spoken night majority it’s wakening the not This at and aging. is bothered at Harris well-being. this results multiple up their
can To help not impressions recently have around aware However, results and is over million and their a they currently, actively we be launched plan XXX physician. not nocturia potential a treated communication condition begin comprehensive educate are it that are that sufferers discussing this to-date. with patients, these to reached
outset, education educate isolated As is and also have must nocturia such the around not well. on stated from We as we NOCTIVA.
clear know demand tremendous effectively from effective professionals is We that build is a the continuing we to helping patients healthcare doing and required of physicians from need world to and are high clinical can with experience efficiently focused the address NOCTIVA on patients data real for and patients. need. and both this and actual There potential and targeted
to our opportunity. Although meaningful not NOCTIVA that draw early been that total on We we in must be has and opportunity and this are where educate market, our work hard them approximately done to too X build-out fully that far of is to be, months promotion ago NOCTIVA, revenue launch the physicians progress firmly and unique there prescriptions both creating while a provides. expect commenced it long-term to new conclusions NOCTIVA believe recognized
I over CFO, Kanan, hospital to let Mike before a on Now our the franchise. hand our call provide few remarks me
provide the fact to both streams. each today, in not are opportunities. expected to assessment market and declined additional the target turn the now – of with still has market, market be with past over results the company to with review for all are our business. the the portfolio have our hold you our highly Furthermore, paid this they Kanan I'll call filing our the while fourth dynamics bills is margins are in in leading three position to Mike? potential the respective new UMD we we’d Given continue early still we're in call And quarter's and products. we’ve provide share out QX seen profitable to financial excellent that product competition remiss and cash and still around with some active color on hospital in next Mike to
